Glenmark said its Baddi unit contributes approximately 10 per cent of the revenue of the US sales.
"The Baddi unit of Glenmark Pharmaceuticals underwent an US FDA (US Food and Drug Administration) audit from November 6 -11, 2017. The USFDA issued seven observations through the form 483," Glenmark Pharmaceuticals said in a BSE filing.
More From This Section
"We are in the midst of providing a comprehensive response to the observations and would be replying to the FDA shortly on the observations," it added.
The company, however, did not elaborate on the nature of observations.
The company's stock was trading 2.05 per cent down at Rs 579.10 apiece on the BSE in the morning trade on Tuesday.